Open Access iconOpen Access

REVIEW

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells

ZAHRA NASRPOUR NAVAEI1, GHAZALEH KHALILI-TANHA1, AMIR SADRA ZANGOUEI2, MOHAMMAD REZA ABBASZADEGAN3, MEYSAM MOGHBELI1,3,*

1 Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

* Corresponding Author: MEYSAM MOGHBELI. Email: email

Oncology Research 2021, 29(4), 235-250. https://doi.org/10.32604/or.2022.025323

Abstract

Chemotherapy is one of the main therapeutic modalities for cancer patients. Cisplatin (CDDP), as one of the first-line drugs, is of great importance in the chemotherapy of various tumors. However, a significant percentage of cancer patients are resistant to CDDP treatment. Due to the CDDP side effects on normal tissues, the diagnosis of CDDP resistance is required to suggest the most efficient therapeutic strategies for cancer patients. Several molecular mechanisms and signaling pathways are associated with CDDP response. The PI3K/AKT signaling pathway has a pivotal role in the transmission of extracellular signals into the cells to regulate various pathophysiological processes such as cell proliferation, migration, and drug resistance. In the present review, we summarized all of the studies which have been reported on the role of PI3K/AKT pathway in regulation of CDDP response. It was shown that the PI3K/AKT pathway is mainly involved in CDDP response in lung, ovarian, and gastrointestinal cancers. It was also observed that the non-coding RNAs have a key role in CDDP response by regulation of PI3K/AKT pathway. This review paves the way for suggesting a PI3K/AKT-related panel marker for the prediction of CDDP response in different cancer patients.

Keywords


Cite This Article

APA Style
NAVAEI, Z.N., KHALILI-TANHA, G., ZANGOUEI, A.S., ABBASZADEGAN, M.R., MOGHBELI, M. (2021). PI3K/AKT signaling pathway as a critical regulator of cisplatin response in tumor cells. Oncology Research, 29(4), 235-250. https://doi.org/10.32604/or.2022.025323
Vancouver Style
NAVAEI ZN, KHALILI-TANHA G, ZANGOUEI AS, ABBASZADEGAN MR, MOGHBELI M. PI3K/AKT signaling pathway as a critical regulator of cisplatin response in tumor cells. Oncol Res. 2021;29(4):235-250 https://doi.org/10.32604/or.2022.025323
IEEE Style
Z.N. NAVAEI, G. KHALILI-TANHA, A.S. ZANGOUEI, M.R. ABBASZADEGAN, and M. MOGHBELI, “PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells,” Oncol. Res., vol. 29, no. 4, pp. 235-250, 2021. https://doi.org/10.32604/or.2022.025323



cc Copyright © 2021 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 2313

    View

  • 972

    Download

  • 2

    Like

Share Link